ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.

Medpace pairs double-digit growth, record awards and a strong balance sheet with a rich valuation, raising the question of whether the premium already prices in its outlook.

ICON's 33.2% rally is backed by stronger proposal flow, bookings and backlog, but weaker earnings and margins cloud the recovery.

Medpace posted record Q2 awards and a stronger book-to-bill ratio, but can backlog conversion and study timing turn renewed demand into stronger 2027 growth?

IQV's proprietary data platform and expanding clinical research business support growth, but high debt and liquidity risks keep the investment outlook balanced.

IQV shares jump after Q2 earnings beat, record bookings and higher 2026 guidance, but future gains hinge on execution and backlog conversion.

Icon PLC (ICLR) delivered earnings and revenue surprises of -0.39% and +3.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.